Antihistamines in Rhinitis and Asthma

  • Todor A. Popov
Part of the Allergy Frontiers book series (ALLERGY, volume 5)

Just several years after the concept “allergy” was coined about a century ago [1], histamine was identified by Sir Henry Dale [2] and subsequently emerged as one of the most important allergy substrates. This marked the onset of a spiral of scientific achievements, which resulted in the development of multiple drug formulations used in the prevention and treatment of allergic disorders and in elucidation of the pleiotropic role histamine plays in health and disease.

Histamine belongs to a group of locally produced tissue hormones (including serotonin and others) referred to as “autacoids.” 1 It plays a vital role in the regulation of the many important functions related to circadian influences, adaptation to environment and stress. Conversely, histamine is intimately implicated in the patho-genesis of allergic diseases, which develop as defective systemic trait of genetically predisposed individuals and may have different organ expressions. Airway allergic morbidity in particular accounts for a lot of individual suffering and disability, and poses a substantial economic burden to society [3, 4]. Therefore, the correct prescription of existing antihistamine products and the development of new and more effective formulations devoid of unwanted effects are two important avenues in the global crusade to control these morbidities affecting millions of people.


Allergic Rhinitis Allergy Clin Immunol Nasal Congestion Seasonal Allergic Rhinitis Allergy Asthma Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    von Pirquet C (1906) Allergie. Munchen Med Wehnschr 53: 1457Google Scholar
  2. 2.
    Dale HH, Laidlaw PP (1910) The physiological actions of iminazolethylamine. J Physiol 41: 318–344PubMedGoogle Scholar
  3. 3.
    Passani MB, Giannoni P, Bucherelli C, Baldi E, Blandina P (2007) Histamine in the brain: beyond sleep and memory. Biochem Pharmacol 73: 1113–1122CrossRefPubMedGoogle Scholar
  4. 4.
    Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/ WHO workshop report. Revision 2006. NIH publication no. 02-3659Google Scholar
  5. 5.
    Bousquet J, Van Cauwenberge P, Khaltaev N (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108: S147–S334CrossRefPubMedGoogle Scholar
  6. 6.
    Theoharides TC, Kalogeromitros D (2006) The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 1088: 78–99CrossRefPubMedGoogle Scholar
  7. 7.
    Schwartz LB (2004) Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 257: 65–74CrossRefPubMedGoogle Scholar
  8. 8.
    Walsh GM (2007) Antihistamines (H1 receptor antagonists). Side Effects Drugs Annu 29: 161–167CrossRefGoogle Scholar
  9. 9.
    Jauregui I, Mullol J, Bartra J, del Cuvillo A, Davila I, Montoro J, Sastre J, Valero AL (2006) H1 antihistamines: psychomotor performance and driving. J Investig Allergol Clin Immunol 16: S37–S44Google Scholar
  10. 10.
    Parsons ME, CR Ganellin (2006) Histamine and its receptors. Brit J Pharmacol 147: S127–S135CrossRefGoogle Scholar
  11. 11.
    Ash A, Schild H (1966) Receptors mediating some actions of histamine. Br J Pharmacol 27: 427–439Google Scholar
  12. 12.
    Black W, Dunian W, Durant C, Ganellin C, Parsons E (1972) Definition and antagonism of histamine H2 receptors. Nature 236: 385–390CrossRefPubMedGoogle Scholar
  13. 13.
    Arrang J, Garbarg M, Lancelot J, Lecomte J, Schwartz J (1987) Highly potent and selective ligands for histamine H3 receptors. Nature 327: 117–123CrossRefPubMedGoogle Scholar
  14. 14.
    Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF (2001) Discovery of a novel member of the histamine receptor family. J Mol Pharmacol 59: 427–433Google Scholar
  15. 15.
    Leurs R, Church MK, Taglialatela M (2002) H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 32: 489–498.CrossRefPubMedGoogle Scholar
  16. 16.
    Bovet D, Staub A-M (1937) Protective action of phenol ethers in the course of histamine intoxication. C R Soc Biol (Paris) 124: 547–549 (French)Google Scholar
  17. 17.
    Passalaqua G, Canonica GW, Bousquet J (2002) Structure and classification of H1-antihistamines and overview of their activities. In: Simons FER (ed) Histamine and H1-antihistamines in allergic disease. Marcel Dekker Inc, New York, pp 65–100Google Scholar
  18. 18.
    Hill SJ, Ganellin CR, Timmerman H, Schwartz J-C, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (1997) International Union of Pharmacology. XIII Classification of histamine receptors. Pharmacol Rev 49: 253–278PubMedGoogle Scholar
  19. 19.
    Black JW, Duncan WAM, Durant GJ, Ganellin CR, Parsons ME (1972) Definition and antagonism of histamine H2 -receptors. Nature 236: 385–390CrossRefPubMedGoogle Scholar
  20. 20.
    Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25: 618–625CrossRefPubMedGoogle Scholar
  21. 21.
    Hansel F (1929) Clinical and histopathologic studies of the nose and sinuses in allergy. J Allergy 1: 43–70CrossRefGoogle Scholar
  22. 22.
    Greiner AN, Meltzer EO (2006) Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 118: 985–996CrossRefPubMedGoogle Scholar
  23. 23.
    Bauchau V, Durham SR (2005) Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 60(3):350–353.CrossRefPubMedGoogle Scholar
  24. 24.
    International Rhinitis Management Working Group (1994) International consensus report on diagnosis and management of rhinitis. Allergy 49(19 Suppl): 1–34Google Scholar
  25. 25.
    Kay AB (2001) Allergy and allergic diseases. Second of two parts. New Engl J Med 344: 109–113CrossRefPubMedGoogle Scholar
  26. 26.
    Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, Bagnasco M, Canonica GW (1995) Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 96: 971–979CrossRefPubMedGoogle Scholar
  27. 27.
    Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, Ciprandi G (2000) Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 105: 54–57CrossRefPubMedGoogle Scholar
  28. 28.
    Canonica GW, Ciprandi G (1999) Minimal persistent inflammation may be controlled by ceti-rizine. Ann Allergy Asthma Immunol 83: 445–448PubMedGoogle Scholar
  29. 29.
    Roche N, Chinet TC, Huchon GJ (1997) Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. Eur Respir J 10: 719–726PubMedGoogle Scholar
  30. 30.
    Reed CE, Kita H (2004) The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 114: 997–1008CrossRefPubMedGoogle Scholar
  31. 31.
    van Wijk RG, de Graaf-in ‘t Veld C, Garrelds IM (1999) Nasal hyperreactivity. Rhinology 37: 50–55Google Scholar
  32. 32.
    Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham SR, Fokkens W, Lockey R, Meltzer EO, Mullol J, Naclerio RM, Price D, Simons FER, Vignola AM, Warner JO (2003) Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58: 192–197CrossRefPubMedGoogle Scholar
  33. 33.
    Simons FE, McMillan JL, Simons KJ (1990) A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 h in normal subjects. J Allergy Clin Immunol 86: 540–547.CrossRefPubMedGoogle Scholar
  34. 34.
    Grant JA, Danielson L, Rihoux JP, DeVos C (1999) A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine induced wheal and flare response for 24 h in healthy male subjects. Allergy 54: 700–707CrossRefPubMedGoogle Scholar
  35. 35.
    Popov TA, Dumitrascu D, Bachvarova A, Bocsan C, Dimitrov V, Church MK (2006) A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 55: 241–244CrossRefPubMedGoogle Scholar
  36. 36.
    Bousquet J, Czarlewski W, Cougnard J, Danzig M, Michel FB (1998) Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. Allergy 53: 579–585CrossRefPubMedGoogle Scholar
  37. 37.
    Carlsen KH, Kramer J, Fagertun HE, Larsen S (1993) Loratadine and terfenadine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drug. Allergy 48: 431–436CrossRefPubMedGoogle Scholar
  38. 38.
    Sullivan PW, Follin SL, Nichol MB (2004) Cost-benefit analysis of first-generation antihista-mines in the treatment of allergic rhinitis. Pharmacoeconomics 22: 929–942CrossRefPubMedGoogle Scholar
  39. 39.
    Doherty MM, Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet. 4: 235–253CrossRefGoogle Scholar
  40. 40.
    Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71: 11–20CrossRefPubMedGoogle Scholar
  41. 41.
    Renwick AG (1999) The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 3: 116–124CrossRefGoogle Scholar
  42. 42.
    Nayak AS, Schenkel E (2001) Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56: 1077–1080CrossRefPubMedGoogle Scholar
  43. 43.
    Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW (2001) Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 56: 1068–1070CrossRefPubMedGoogle Scholar
  44. 44.
    Klimek L (2005) Potential of levocetirizine in the relief of nasal congestion. Int J Clin Pract 59: 721–729CrossRefPubMedGoogle Scholar
  45. 45.
    de Blic J, Wahn U, Billard E, Alt R, Pujazon MC (2005) Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 16: 267–275CrossRefPubMedGoogle Scholar
  46. 46.
    Simons FE (2002) H1-antihistamines in children. Clin Allergy Immunol 17: 437–464PubMedGoogle Scholar
  47. 47.
    Cruz AA, Popov TA, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, Bousquet J (2007) Common characteristics of upper and lower airways disease in rhinitis and asthma: ARIA update, in collaboration with GA 2 LEN. Allergy (in press)Google Scholar
  48. 48.
    Gelfand EW (2002) Role of histamine in the pathophysiology of asthma: immunomodulatory and antiinflammatory activities of H1-receptor antagonists. Am J Med 113: 2S–7SCrossRefPubMedGoogle Scholar
  49. 49.
    Larsen JS (2001) Do antihistamines have a role in asthma therapy? Pharmacotherapy. 21: 28S–33SCrossRefPubMedGoogle Scholar
  50. 50.
    Borade PS, Ballary CC, Currie GP, Lee DKC (2006) Modern H1-antihistamines in asthma. Drug Discov Today: Ther Strateg 3: 253–259CrossRefGoogle Scholar
  51. 51.
    Borade PS, Ballary CC, Currie GP, Lee DKC (2006) Modern H1 -antihistamines in asthma. Drug Discov Today: Ther Strateg 3: 253–259CrossRefGoogle Scholar
  52. 52.
    Aubier M, Neukirch C, Peiffer C, Melac M (2001) Effect of cetirizine on bronchial hyperre-sponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 56: 35–42CrossRefPubMedGoogle Scholar
  53. 53.
    Berger WE, Schenkel EJ, Mansfield LE (2002) Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 89: 485–491PubMedGoogle Scholar
  54. 54.
    Baena-Cagnani CE, Berger WE, DuBuske LM, Gurne SE, Stryszak P, Lorber R, Danzig M (2003) Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 130: 307–313CrossRefPubMedGoogle Scholar
  55. 55.
    Spaeth J, Klimek L, Mosges R (1996) Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 51: 893–906PubMedGoogle Scholar
  56. 56.
    Gelfand EW (2005) Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 84(3): 163–168PubMedGoogle Scholar
  57. 57.
    McCue JD (1996) Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. Arch Fam Med 5: 464–468CrossRefPubMedGoogle Scholar
  58. 58.
    Schatz M (1998) Special considerations for the pregnant woman and senior citizen with airway disease. J Allergy Clin Immunol 101: S373–S378CrossRefPubMedGoogle Scholar
  59. 59.
    Demoly P, Piette V, Daures JP (2003) Treatment of allergic rhinitis during pregnancy. Drugs 63: 1813–1820CrossRefPubMedGoogle Scholar
  60. 60.
    Joint committee of the American College of Obstetricians and Gynecologoists (ACOG) and the American College of Allergy (ACAAI) (2000) The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol 84: 475–480CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Clinic of Allergy and AsthmaAlexander's University HospitalSofiaBulgaria

Personalised recommendations